-
Abemaciclib, sold
under the
brand name
Verzenio among others, is a
medication for the
treatment of
advanced or
metastatic breast cancers. It was developed...
- HR-positive, HER2-negative
advanced breast cancer in
combination with
abemaciclib or
palbociclib in
women with
disease progression after endocrine therapy...
-
notable pharmaceutical agents which contain a
benzimidazole group include abemaciclib, bendamustine, dabigatran, daridorexant, and glasdegib. In
printed circuit...
- used in
combination with CDK4/6
inhibitors (palbociclib, ribociclib, or
abemaciclib). When one
endocrine therapy fails, most will
benefit from transitioning...
-
undergoing clinical trials. A
phase II
clinical study investigating abemaciclib is
underway in
patients with
pretreated or
untreated DDL. Preliminary...
- L01EE05
Mirdametinib L01EF01
Palbociclib L01EF02
Ribociclib L01EF03
Abemaciclib L01EG01
Temsirolimus L01EG02
Everolimus L01EG03
Ridaforolimus L01EG04...
-
Enzyme inhibitors FI (Tipifarnib§) CDK
inhibitors (
Abemaciclib Alvocidib†
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib...
-
being studied for the
treatment of cancer. It has a
similar structure to
abemaciclib but is more
selective for CDK4/6 over CDK9
according to
preclinical research...
- effectiveness.
Three Cdk4/6
inhibitors – palbociclib, ribociclib, and
abemaciclib –
currently received FDA
approval for
clinical use to
treat advanced-stage...
-
Enzyme inhibitors FI (Tipifarnib§) CDK
inhibitors (
Abemaciclib Alvocidib†
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib...
